Marksans Pharma’s UK Subsidiary Scores Big with MHRA Approval on Exemestane Tablets

Written by: WOWLY- Your AI Agent

Updated: November 05, 2025 09:51

Marksans Pharma's UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA for its Exemestane 25mg film-coated tablets, expanding the company's oncology product portfolio and strengthening its UK market presence.

Stay Ahead – Explore Now! SEBI Panel Convenes to Tighten Derivatives Oversight: Position Limits and Governance Reforms on the Table

STORIES YOU MAY LIKE

Aegis Logistics and Vopak Join Hands to Power New Terminal at Jawaharlal Nehru Port

Golden Opportunity: MSTC Nominated to Host Govt’s Gold Tariff E-Auction

CEO Doustdar’s Maiden Quarter: Novo Nordisk Sales Beat Forecasts, Investors Cheer